NON-INVASIVE TOOLS FOR CVD SCREENING AND MONITORING
Dr Hadi Afsharan,
Research Fellow
University of Western Australia &
Harry Perkins Institute of Medical Research,
Perth, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | November 2025
Dr Hadi Afsharan is a Research Fellow Cardiovascular Science & Diabetes at the Harry Perkins Institute of Medical Research; is a translational research and innovation fellow in medical technologies at The University of Western Australia, holding dual titles as Translational Fellow and Innovation Fellow within UWA’s Medical School and the FHRI (Future Health Research and Innovation) program.
He earned his PhD in Biomedical Engineering from UWA in 2023, with a thesis entitled Development of Polarisation-Sensitive Optical Coherence Tomography for Application in Medical Diagnosis, which introduced a pioneering non-invasive imaging method for detecting hypertension and diabetes by analysing retinal blood vessel wall birefringence with exceptional sensitivity and specificity.
Hadi leads several translational research projects, including AI-based retinal biomarkers for coronary artery disease screening, low-cost imaging technologies for heart disease detection in remote communities, and radar-based non-contact measurement of jugular venous pressure, all supported by over $1.8 million in competitive funding from FHRI and UWA.
Source: Supplied
https://orcid.org/0000-0001-7874-2766
-
Health and economic burden of interstitial lung diseases
Dr Cox’s main research interests focus on respiratory diseases and primarily on the economic burden and economic evaluation of interventions and treatments for their management. She earned her PhD from the University of Tasmania where her doctoral research examined the health and economic burden of idiopathic pulmonary fibrosis (IPF) in Australia, one component of the NHMRC Centre for Research Excellence for Pulmonary Fibrosis, a national project implemented alongside the Australian IPF Registry and the Lung Foundation Australia. This research provided the first epidemiological profile and first costing estimates of the economic burden of the disease in Australia, providing essential evidence for health service reimbursement policies.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Antimicrobial technologies & drug delivery platforms
Dr Aaron Elbourne is an ARC DECRA Fellow, Jack Brockhoff ECR Fellow, and Associate Professor within the School of Science at STEM Hub. A leader in nanomaterials, soft matter science, and interface research, Aaron’s work addresses critical challenges in health and the environment.
With a strong focus on translational research, Aaron’s work bridges the gap between fundamental science and practical applications. His leadership in creating innovative technologies, fostering academic-industry partnerships, and empowering future researchers underscores his commitment to advancing science and creating a meaningful impact.
